Clinical trial
Bortezomib in Treating Patients With Newly Diagnosed Multiple Myeloma
NCT00075881 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00075881 |
|---|---|
| Title | Bortezomib in Treating Patients With Newly Diagnosed Multiple Myeloma |
| Official title | Phase II Study of PS-341 for Patients With High-Risk, Newly Diagnosed Multiple Myeloma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma |
| Intervention type | Drug, Other |
| Interventions | bortezomib, laboratory biomarker analysis |
| Enrollment | 44 |
| Start date | Jan 1, 2004 |
| Primary completion | Oct 1, 2012 |
| Completion | Oct 1, 2012 |
| First posted | Jan 13, 2004 |
| Last update posted | Jun 2, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: